BMY.N
現在値
72.99USD変化
-0.18(-0.25%)出来高
1,724,863本日のレンジ
-
73.2052週レンジ
-
81.43∙ 約20分前の相場を表示しています。
Jan 18 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::ENTERS MASTER SERVICE AGREEMENT AND NEW CLINICAL TRIAL RECRUITMENT CONTRACTS WITH BRISTOL MYERS SQUIBB.
Dec 8 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB ANNOUNCES DIVIDEND INCREASE.BRISTOL MYERS SQUIBB ANNOUNCES DIVIDEND INCREASE.BRISTOL-MYERS SQUIBB CO - BOARD OF DIRECTORS HAS DECLARED A QUARTERLY DIVIDEND OF $0.57 PER SHARE ON COMMON STOCK.BRISTOL-MYERS SQUIBB CO - QUARTERLY DIVIDEND REPRESENTS A 5.6% INCREASE OVER LAST YEAR'S QUARTERLY DIVIDEND RATE OF $0.54 PER SHARE.
Nov 14 (Reuters) - Adage Capital Partners GP LLC: :ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN DOMINOS PIZZA INC BY 95.2 PERCENT TO 100,739 SHARES.ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN JPMORGAN CHASE & CO BY 22.6 PERCENT TO 2.3 MILLION SHARES.ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN BRISTOL-MYERS SQUIBB CO TO 2.2 MILLION SHARES FROM 997,060 SHARES.ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN GENERAL MOTORS CO BY 24.2 PERCENT TO 1.9 MILLION SHARES.ADAGE CAPITAL PARTNERS GP LLC CUTS SHARE STAKE IN GOLDMAN SACHS GROUP INC BY 14.7 PERCENT TO 360,209 SHARES.ADAGE CAPITAL PARTNERS GP LLC CUTS SHARE STAKE IN EXXONMOBIL BY 19.7 PERCENT TO 5.5 MILLION SHARES.ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN PAYSAFE LIMITED BY 62.9 PCT TO 4.1 MILLION SHARES.ADAGE CAPITAL PARTNERS GP LLC - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2022 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2022.
Nov 3 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::KURA ONCOLOGY ANNOUNCES FINANCING TRANSACTIONS WITH BRISTOL MYERS SQUIBB AND HERCULES CAPITAL, PROVIDING ACCESS TO UP TO $150 MILLION.KURA ONCOLOGY INC - PROCEEDS EXTEND KURA'S CASH RUNWAY INTO 2026, IF TERM LOAN IS FULLY DRAWN.KURA ONCOLOGY INC - $25 MILLION EQUITY INVESTMENT FROM BRISTOL MYERS SQUIBB AT $18.25 PER SHARE.KURA ONCOLOGY INC - TERM LOAN FACILITY FROM HERCULES CAPITAL PROVIDES UP TO $125 MILLION.KURA ONCOLOGY INC - $25 MILLION EQUITY INVESTMENT FROM BRISTOL MYERS SQUIBB AT $18.25 PER SHARE.KURA ONCOLOGY INC - TERM LOAN FACILITY FROM HERCULES CAPITAL PROVIDES UP TO $125 MILLION.KURA ONCOLOGY INC - PROCEEDS EXTEND KURA'S CASH RUNWAY INTO 2026, IF TERM LOAN IS FULLY DRAWN.
Oct 31 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE 3 COMMANDS TRIAL.BRISTOL-MYERS SQUIBB CO - REBLOZYL, FIRST ERYTHROID MATURATION AGENT, MET PRIMARY AND KEY SECONDARY ENDPOINTS.BRISTOL-MYERS SQUIBB CO - SAFETY RESULTS IN TRIAL WERE CONSISTENT WITH SAFETY PROFILE OF REBLOZYL PREVIOUSLY DEMONSTRATED IN MEDALIST STUDY.
Oct 27 (Reuters) - Obsidian Therapeutics: :OBSIDIAN THERAPEUTICS ANNOUNCES EXTENSION OF MULTI-YEAR COLLABORATION AGREEMENT WITH BRISTOL MYERS SQUIBB.OBSIDIAN THERAPEUTICS ANNOUNCES EXTENSION OF MULTI-YEAR COLLABORATION AGREEMENT WITH BRISTOL MYERS SQUIBB.
Oct 25 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB - QTRLY TOTAL REVENUE $11.22 BILLION, DOWN 3%.BRISTOL MYERS SQUIBB - QTRLY EARNINGS PER SHARE $0.75; QTRLY ADJUSTED EARNINGS PER SHARE $1.99.BRISTOL MYERS SQUIBB - QTRLY REVLIMID REVENUE $2.42 BILLION VERSUS $3.35 BILLION.BRISTOL MYERS SQUIBB - QTRLY OPDIVO REVENUE $2.05 BILLION VERSUS $1.91 BILLION.BRISTOL MYERS SQUIBB - QTRLY ELIQUIS REVENUE $2.66 BILLION VERSUS $2.41 BILLION.BRISTOL MYERS SQUIBB - SEES FY EPS OF $2.54 TO $2.84.BRISTOL MYERS SQUIBB - REAFFIRMS FY NON-GAAP EPS GUIDANCE.Further company coverage: BMY.N. ((Reuters.Briefs@thomsonreuters.com;)).
Oct 24 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB CO - ANNOUNCED NEW POST HOC ANALYSES FROM PHASE 3 TRUE NORTH STUDY.BRISTOL-MYERS SQUIBB CO - CONTINUOUS ZEPOSIA TREATMENT PREVENTS DISEASE RELAPSE OVER 1 YEAR IN 86.1% OF PATIENTS WHO RESPOND AT END OF INDUCTION PERIOD.BRISTOL-MYERS SQUIBB CO - ZEPOSIA MAINTAINS DISEASE CONTROL EVEN IN EVENT OF TEMPORARY TREATMENT INTERRUPTION FOR UP TO EIGHT WEEKS.
Oct 4 (Reuters) - Exelixis Inc <EXEL.O>::EXELIXIS EXPANDS CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BRISTOL MYERS SQUIBB TO INCLUDE THE FIXED-DOSE COMBINATION OF NIVOLUMAB AND RELATLIMAB IN COMBINATION WITH XL092 IN PHASE 1B STELLAR-002 TRIAL.EXELIXIS INC - AGREEMENT ENABLES EVALUATION OF XL092 IN COMBINATION WITH AN ADDITIONAL IMMUNE CHECKPOINT INHIBITOR.EXELIXIS INC - EXELIXIS IS SPONSORING STELLAR-002, BRISTOL MYERS SQUIBB WILL PROVIDE FIXED-DOSE COMBINATION OF NIVOLUMAB AND RELATLIMAB.EXELIXIS INC - ENROLLMENT AND DOSING IN DOSE-ESCALATION PORTION OF STELLAR-002 IS ONGOING.
Sept 15 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB ANNOUNCES ADJUVANT TREATMENT WITH OPDIVO (NIVOLUMAB) DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN RECURRENCE-FREE SURVIVAL (RFS) IN PATIENTS WITH STAGE IIB/C MELANOMA IN THE CHECKMATE -76K TRIAL.BRISTOL-MYERS SQUIBB CO - POSITIVE RESULTS FROM CHECKMATE -76K REINFORCE POTENTIAL BENEFIT OF OPDIVO IN EARLIER STAGES OF MELANOMA.BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY SIGNALS WERE OBSERVED AT TIME OF ANALYSIS.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。